Setting

Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247651 | Pages: 123

Europe antibiotics market accounted for $11.65 billion in 2019 and will grow by 3.4% annually over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic. Highlighted with 35 tables and 59 figures, this 123-page report “Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country. Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cephalosporin • Penicillin • Macrolides • Fluoroquinolones • Quinolones • Monobactam • Aminoglycosides • Carbapenem • Other Drug Classes Based on Action Mechanism, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Intravenous Administration • Other Administration Routes Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on the Market	21
2.2 Major Growth Drivers	23
2.3 Market Restraints and Challenges	27
2.4 Emerging Opportunities and Market Trends	30
2.5 Porter’s Fiver Forces Analysis	34
3 Segmentation of Europe Market by Drug Class	38
3.1 Market Overview by Drug Class	38
3.2 Cephalosporin	40
3.3 Penicillin	41
3.4 Macrolides	42
3.5 Fluoroquinolones	43
3.6 Quinolones	44
3.7 Monobactam	45
3.8 Aminoglycosides	46
3.9 Carbapenem	47
3.10 Other Drug Classes	48
4 Segmentation of Europe Market by Action Mechanism	49
4.1 Market Overview by Action Mechanism	49
4.2 Cell Wall Synthesis Inhibitors	51
4.3 Mycolic Acid Inhibitors	52
4.4 RNA Synthesis Inhibitors	53
4.5 DNA Synthesis Inhibitors	54
4.6 Protein Synthesis Inhibitors	55
4.7 Other Mechanisms	56
5 Segmentation of Europe Market by Drug Origin	57
5.1 Market Overview by Drug Origin	57
5.2 Natural Antibiotics	59
5.3 Semi-synthetic Antibiotics	60
5.4 Synthetic Antibiotics	61
6 Segmentation of Europe Market by Activity Spectrum	62
6.1 Market Overview by Activity Spectrum	62
6.2 Broad-spectrum Antibiotics	64
6.3 Narrow-spectrum Antibiotics	65
7 Segmentation of Europe Market by Route of Administration	66
7.1 Market Overview by Route of Administration	66
7.2 Oral Administration	68
7.3 Intravenous Administration	69
7.4 Other Administration Routes	70
8 Segmentation of Europe Market by Drug Type	71
8.1 Market Overview by Drug Type	71
8.2 Brand Antibiotics	73
8.3 Generic Antibiotics	74
9 European Market 2019-2030 by Country	75
9.1 Overview of European Market	75
9.2 Germany	78
9.3 UK	80
9.4 France	83
9.5 Spain	85
9.6 Italy	87
9.7 Russia	89
9.8 Rest of European Market	91
10 Competitive Landscape	93
10.1 Overview of Key Vendors	93
10.2 New Product Launch, Partnership, Investment, and M&A	96
10.3 Company Profiles	97
Abbott Laboratories	97
Astellas Pharma	99
AstraZeneca Plc	100
Bayer AG	101
Bristol Myers Squibb Company	102
Cipla Inc.	103
Dr. Reddy’s Laboratories Ltd.	104
Eli Lilly and Company	105
F. Hoffmann-La Roche Ltd.	106
Gilead Sciences, Inc.	107
GlaxoSmithKline plc.	108
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	109
Mayne Pharma Group Ltd.	110
MELINTA THERAPEUTICS, INC.	111
Merck KGaA	112
Novartis AG	113
Pfizer Inc.	114
Sanofi	115
Sun Pharmaceutical Industries Ltd.	116
11 Investing in Europe Market: Risk Assessment and Management	117
11.1 Risk Evaluation of Europe Market	117
11.2 Critical Success Factors (CSFs)	120
Related Reports and Products	123
List Of Tables

Table 1.  Snapshot of Europe Antibiotics Market, 2019-2030	18
Table 2.  Main Product Trends and Market Opportunities in Europe Antibiotics Market	30
Table 3. Europe Antibiotics Market by Drug Class, 2019-2030, $ mn	38
Table 4. Europe Antibiotics Market by Action Mechanism, 2019-2030, $ mn	49
Table 5. Europe Antibiotics Market by Drug Origin, 2019-2030, $ mn	57
Table 6. Europe Antibiotics Market by Activity Spectrum, 2019-2030, $ mn	62
Table 7. Europe Antibiotics Market by Route of Administration, 2019-2030, $ mn	66
Table 8. Europe Antibiotics Market by Drug Type, 2019-2030, $ bn	71
Table 9. Europe Antibiotics Market by Country, 2019-2030, $ bn	77
Table 10. Germany Antibiotics Market by Drug Class, 2019-2030, $ mn	79
Table 11. Germany Antibiotics Market by Drug Origin, 2019-2030, $ mn	79
Table 12. Germany Antibiotics Market by Route of Administration, 2019-2030, $ mn	79
Table 13. UK Antibiotics Market by Drug Class, 2019-2030, $ mn	82
Table 14. UK Antibiotics Market by Drug Origin, 2019-2030, $ mn	82
Table 15. UK Antibiotics Market by Route of Administration, 2019-2030, $ mn	82
Table 16. France Antibiotics Market by Drug Class, 2019-2030, $ mn	84
Table 17. France Antibiotics Market by Drug Origin, 2019-2030, $ mn	84
Table 18. France Antibiotics Market by Route of Administration, 2019-2030, $ mn	84
Table 19. Spain Antibiotics Market by Drug Class, 2019-2030, $ mn	86
Table 20. Spain Antibiotics Market by Drug Origin, 2019-2030, $ mn	86
Table 21. Spain Antibiotics Market by Route of Administration, 2019-2030, $ mn	86
Table 22. Italy Antibiotics Market by Drug Class, 2019-2030, $ mn	88
Table 23. Italy Antibiotics Market by Drug Origin, 2019-2030, $ mn	88
Table 24. Italy Antibiotics Market by Route of Administration, 2019-2030, $ mn	88
Table 25. Russia Antibiotics Market by Drug Class, 2019-2030, $ mn	90
Table 26. Russia Antibiotics Market by Drug Origin, 2019-2030, $ mn	90
Table 27. Russia Antibiotics Market by Route of Administration, 2019-2030, $ mn	90
Table 28. Antibiotics Market in Rest of Europe by Country, 2019-2030, $ bn	92
Table 29. Abbott Laboratories: Company Snapshot	97
Table 30. Abbott Laboratories: Business Segmentation	97
Table 31. Abbott Laboratories: Product Portfolio	98
Table 32. Abbott Laboratories: Revenue, 2016-2018, $ mn	98
Table 33. Abbott Laboratories: Recent Developments	98
Table 34.  Risk Evaluation for Investing in Europe Market, 2019-2030	118
Table 35. Critical Success Factors and Key Takeaways	121
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Europe Antibiotics Market, 2019-2030, $ mn	20
Figure 6. Impact of COVID-19 on Business	21
Figure 7. Primary Drivers and Impact Factors of Europe Antibiotics Market	23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand	26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million	26
Figure 10. Primary Restraints and Impact Factors of Europe Antibiotics Market	27
Figure 11. Investment Opportunity Analysis	31
Figure 12. Porter’s Fiver Forces Analysis of Europe Antibiotics Market	34
Figure 13. Breakdown of Europe Antibiotics Market by Drug Class, 2019-2030, % of Revenue	39
Figure 14. Europe Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)	39
Figure 15. Europe Antibiotics Market: Cephalosporin, 2019-2030, $ mn	40
Figure 16. Europe Antibiotics Market: Penicillin, 2019-2030, $ mn	41
Figure 17. Europe Antibiotics Market: Macrolides, 2019-2030, $ mn	42
Figure 18. Europe Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn	43
Figure 19. Europe Antibiotics Market: Quinolones, 2019-2030, $ mn	44
Figure 20. Europe Antibiotics Market: Monobactam, 2019-2030, $ mn	45
Figure 21. Europe Antibiotics Market: Aminoglycosides, 2019-2030, $ mn	46
Figure 22. Europe Antibiotics Market: Carbapenem, 2019-2030, $ mn	47
Figure 23. Europe Antibiotics Market: Other Drug Classes, 2019-2030, $ mn	48
Figure 24. Breakdown of Europe Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue	50
Figure 25. Europe Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)	50
Figure 26. Europe Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn	51
Figure 27. Europe Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn	52
Figure 28. Europe Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn	53
Figure 29. Europe Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn	54
Figure 30. Europe Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn	55
Figure 31. Europe Antibiotics Market: Other Mechanisms, 2019-2030, $ mn	56
Figure 32. Breakdown of Europe Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue	58
Figure 33. Europe Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)	58
Figure 34. Europe Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn	59
Figure 35. Europe Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn	60
Figure 36. Europe Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn	61
Figure 37. Breakdown of Europe Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue	63
Figure 38. Europe Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)	63
Figure 39. Europe Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn	64
Figure 40. Europe Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn	65
Figure 41. Breakdown of Europe Antibiotics Market by Route of Administration, 2019-2030, % of Revenue	67
Figure 42. Europe Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%)	67
Figure 43. Europe Antibiotics Market: Oral Administration, 2019-2030, $ mn	68
Figure 44. Europe Antibiotics Market: Intravenous Administration, 2019-2030, $ mn	69
Figure 45. Europe Antibiotics Market: Other Administration Routes, 2019-2030, $ mn	70
Figure 46. Breakdown of Europe Antibiotics Market by Drug Type, 2019-2030, % of Revenue	71
Figure 47. Europe Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)	72
Figure 48. Europe Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn	73
Figure 49. Europe Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn	74
Figure 50. Breakdown of European Antibiotics Market by Country, 2019 and 2030, % of Revenue	76
Figure 51. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	77
Figure 52.  Antibiotics Market in Germany, 2019-2030, $ bn	78
Figure 53.  Antibiotics Market in UK, 2019-2030, $ bn	80
Figure 54.  Antibiotics Market in France, 2019-2030, $ bn	83
Figure 55.  Antibiotics Market in Spain, 2019-2030, $ bn	85
Figure 56.  Antibiotics Market in Italy, 2019-2030, $ bn	87
Figure 57.  Antibiotics Market in Russia, 2019-2030, $ bn	89
Figure 58.  Antibiotics Market in Rest of Europe, 2019-2030, $ bn	91
Figure 59. Growth Stage of Europe Antibiotics Industry over the Forecast Period	93
Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories	
Astellas Pharma	
AstraZeneca Plc	
Bayer AG	
Bristol Myers Squibb Company	
Cipla Inc.	
Dr. Reddy’s Laboratories Ltd.	
Eli Lilly and Company	
F. Hoffmann-La Roche Ltd.	
Gilead Sciences, Inc.	
GlaxoSmithKline plc.	
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)	
Mayne Pharma Group Ltd.	
MELINTA THERAPEUTICS, INC.	
Merck KGaA	
Novartis AG	
Pfizer Inc.	
Sanofi	
Sun Pharmaceutical Industries Ltd.